Back to Search
Start Over
Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
- Source :
-
Transplant Infectious Disease . Feb2024, Vol. 26 Issue 1, p1-6. 6p. - Publication Year :
- 2024
-
Abstract
- The triazole antifungal isavuconazole (ISAVU) is used for prevention and treatment of fungal infections in solid organ transplant (SOT). SOT recipients commonly need to transition from one azole to another due to breakthrough infection, toxicity, or other reasons. The purpose of our study was to evaluate the effect of ISAVU on immunosuppressant concentrations in thoracic transplant recipients when ISAVU was started de novo or transitioned from another azole. We conducted a single‐center retrospective cohort study including 68 patients (51 lung, 14 heart, and 3 heart/lung transplant). Concentration to dosage ratios (C/D) of immunosuppressants were assessed at baseline, day 3, and weekly for 9 weeks. When starting ISAVU de novo, we observed a temporary doubling of tacrolimus exposure. Cyclosporine and sirolimus required dose decreases. Tacrolimus C/D increased by 110% at day 3 in patients started on ISAVU de novo then returned to baseline C/D ± 17% weeks 2‐9 (n = 8). One cyclosporine patient started on ISAVU de novo had variable C/D, and C/D increased by 219% ± 72% in 2 sirolimus patients. When transitioning from other azoles, tacrolimus and cyclosporine required about twice the initial dose. After week 1, tacrolimus C/D decreased by 53% ± 6% in patients transitioned from posaconazole (n = 33), voriconazole (n = 14), or fluconazole (n = 2). Cyclosporine C/D decreased by 45% ± 16% in patients transitioning from other azoles (posaconazole [n = 2], voriconazole [n = 2], fluconazole [n = 1]). Sirolimus C/D decreased by 73% ± 13% in patients transitioned from posaconazole (n = 7). Aside from the initial loading phase, ISAVU had a lesser degree of interaction with immunosuppressants than other azoles in loading phase, ISAVU had a lesser degree of interaction with immunosuppressants than other azoles in adjustments for the 4‐week period after initiating antifungal therapy with ISAVU or switching from another agent. [ABSTRACT FROM AUTHOR]
- Subjects :
- *AZOLES
*BREAKTHROUGH infections
*RAPAMYCIN
*LUNG transplantation
*VORICONAZOLE
Subjects
Details
- Language :
- English
- ISSN :
- 13982273
- Volume :
- 26
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Transplant Infectious Disease
- Publication Type :
- Academic Journal
- Accession number :
- 175446632
- Full Text :
- https://doi.org/10.1111/tid.14209